Top

BMC Cancer

Published in:

Open Access 01-12-2019 | Metastasis | Research article

Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells

Authors: Xuechen Yu, Chuan Liang, Yuanzhen Zhang, Wei Zhang, Huijun Chen

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

We aimed to develop inhibitory short peptides that can prevent protein interactions of SOS1/EPS8/ABI1 tri-complex, a key component essential for ovarian cancer metastasis.

Methods

Plasmids containing various regions of HA-tagged ABI1 were co-transfected into ovarian cancer cells with Flag-tagged SOS1 or Myc-tagged EPS8. Co-immunoprecipitation and GST-pulldown assay were used to identify the regions of ABI1 responsible for SOS1 and EPS8 binding. Inhibitory short peptides of these binding regions were synthesized and modified with HIV-TAT sequence. The blocking effects of the peptides on ABI1-SOS1 or ABI1-EPS8 interactions in vitro and in vivo were determined by GST-pulldown assay. The capability of these short peptides in inhibiting invasion and metastasis of ovarian cancer cell was tested by Matrigel invasion assay and peritoneal metastatic colonization assay.

Results

The formation of endogenous SOS1/EPS8/ABI1 tri-complex was detected in the event of LPA-induced ovarian cancer cell invasion. In the tri-complex, ABI1 acted as a scaffold protein holding together SOS1 and EPS8. The SH3 and poly-proline+PxxDY regions of ABI1 were responsible for SOS1 and EPS8 binding, respectively. Inhibitory short peptides p + p-8 (ppppppppvdyedee) and SH3–3 (ekvvaiydytkdkddelsfmegaii) could block ABI1-SOS1 and ABI1-EPS8 interaction in vitro. TAT-p + p-8 peptide could disrupt ABI1-EPS8 interaction and suppress the invasion and metastasis of ovarian cancer cells in vivo.

Conclusions

TAT-p + p-8 peptide could efficiently disrupt the ABI1-EPS8 interaction, tri-complex formation, and block the invasion and metastasis of ovarian cancer cells.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. https://doi.org/10.3322/caac.21208.CrossRefPubMed

Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. ESMO Guidelines Committee. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv1–iv18. https://doi.org/10.1093/annonc/mdy001.CrossRefPubMed

Argento M, Hoffman P, Gauchez AS. Ovarian cancer detection and treatment: current situation and future prospects. Anticancer Res. 2008;28(5B):3135–8.PubMed

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719–25. https://doi.org/10.1038/nrc3144.CrossRefPubMedPubMedCentral

Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26(6):995–1005. https://doi.org/10.1200/JCO.2006.07.9970.CrossRefPubMed

Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–64. https://doi.org/10.2353/ajpath.2010.100105.CrossRefPubMedPubMedCentral

Jesionowska A, Cecerska-Heryc E, Matoszka N, Dolegowska B. Lysophosphatidic acid signaling in ovarian cancer. J Recept Signal Transduct Res. 2015;35(6):578–84. https://doi.org/10.3109/10799893.2015.1026444.CrossRefPubMed

Pua TL, Wang FQ, Fishman DA. Roles of LPA in ovarian cancer development and progression. Future Oncol. 2009;5(10):1659–73. https://doi.org/10.2217/fon.09.120.CrossRefPubMed

Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002;1582(1–3):257–64.CrossRefPubMed

10.

Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Xu Y, et al. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells andlysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res. 2006;66(16):7983–90.CrossRefPubMed

11.

Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst. 2008;100(22):1630–42. https://doi.org/10.1093/jnci/djn378.CrossRefPubMedPubMedCentral

12.

Wang P, Wu X, Chen W, Liu J, Wang X. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol. 2007;104(3):714–20.CrossRefPubMed

13.

Yu X, Zhang Y, Chen H. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. BMC Cancer. 2016;16(1):846.CrossRefPubMedPubMedCentral

14.

Chen H, Wu X, Pan ZK, Huang S. Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis. Cancer Res. 2010;70(23):9979–90. https://doi.org/10.1158/0008-5472.CrossRefPubMedPubMedCentral

15.

Pierre S, Bats AS, Coumoul X. Understanding SOS (son of Sevenless). Biochem Pharmacol. 2011;82(9):1049–56. https://doi.org/10.1016/j.bcp.2011.07.072.CrossRefPubMed

16.

Schmidt A, Hall A. Guanine nucleotide exchange factors for rho GTPases: turning on the switch. Genes Dev. 2002;16(13):1587–609.CrossRefPubMed

17.

Innocenti M, Tenca P, Frittoli E, Faretta M, Tocchetti A, Di Fiore PP, et al. Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. J Cell Biol. 2002;156(1):125–36.CrossRefPubMedPubMedCentral

18.

Innocenti M, Frittoli E, Ponzanelli I, Falck JR, Brachmann SM, Di Fiore PP, et al. Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J Cell Biol. 2003;160(1):17–23.CrossRefPubMedPubMedCentral

19.

Mitra S, Lee JS, Cantrell M, Van den Berg CL. C-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). J Biol Chem. 2011;286(17):15287–97. https://doi.org/10.1074/jbc.M109.094441.CrossRefPubMedPubMedCentral

20.

Scita G, Nordstrom J, Carbone R, Tenca P, Giardina G, Gutkind S, et al. EPS8 and E3B1 transduce signals from Ras to Rac. Nature. 1999;401(6750):290–3.CrossRefPubMed

21.

Di Fiore PP, Scita G. Eps8 in the midst of GTPases. Int J Biochem Cell Biol. 2002;34(10):1178–83.CrossRefPubMed

22.

Scita G, Tenca P, Areces LB, Tocchetti A, Frittoli E, Giardina G, et al. An effector region in Eps8 is responsible for the activation of the Rac-specific GEF activity of Sos-1 and for the proper localization of the Rac-based actin-polymerizing machine. J Cell Biol. 2001;154(5):1031–44.CrossRefPubMedPubMedCentral

23.

Li YH, Xue TY, He YZ, Du JW. Novel oncoprotein EPS8: a new target for anticancer therapy. Future Oncol. 2013;9(10):1587–94. https://doi.org/10.2217/fon.13.104.CrossRefPubMed

24.

Kotula L. Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling. FEBS Lett. 2012;586(17):2790–4. https://doi.org/10.1016/j.febslet.2012.05.015.CrossRefPubMedPubMedCentral

25.

Fan PD, Goff SP. Abl interactor 1 binds to sos and inhibits epidermal growth factor- and v-Abl-induced activation of extracellular signal-regulated kinases. Mol Cell Biol. 2000;20(20):7591–601.CrossRefPubMedPubMedCentral

26.

Mongioví AM, Romano PR, Panni S, Mendoza M, Wong WT, Musacchio A, et al. A novel peptide-SH3 interaction. EMBO J. 1999;18(19):5300–9.CrossRefPubMedPubMedCentral

27.

Ahram M, Mustafa E, Zaza R, Abu Hammad S, Alhudhud M, Bawadi R, et al. Differential expression and androgen regulation of microRNAs and metalloprotease 13 in breast cancer cells. Cell Biol Int. 2017;41(12):1345–55. https://doi.org/10.1002/cbin.10841.CrossRefPubMed

28.

Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(1):126–36. https://doi.org/10.1038/s41391-018-0035-z.CrossRefPubMedPubMedCentral

29.

Stone TA, Deber CM. Therapeutic design of peptide modulators of protein-protein interactions in membranes. Biochim Biophys Acta Biomembr. 2017;1859(4):577–85. https://doi.org/10.1016/j.bbamem.2016.08.013.CrossRefPubMed

30.

Meireles LM, Mustata G. Discovery of modulators of protein-protein interactions: current approaches and limitations. Curr Top Med Chem. 2011;11(3):248–57.CrossRefPubMed

31.

Cunningham AD, Qvit N, Mochly-Rosen D. Peptides and peptidomimetics as regulators of protein-protein interactions. Curr Opin Struct Biol. 2017;44:59–66. https://doi.org/10.1016/j.sbi.2016.12.009.CrossRefPubMedPubMedCentral

32.

Helmer D, Schmitz K. Peptides and peptide analogs to inhibit protein-protein interactions. Adv Exp Med Biol. 2016;917:147–83. https://doi.org/10.1007/978-3-319-32805-8_8.CrossRefPubMed

33.

Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122–8. https://doi.org/10.1016/j.drudis.2014.10.003.CrossRefPubMed

34.

llert-Miklaszewska A, Poleszak K, Kaminska B. Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment. Future Med Chem. 2017;9(2):199–221. https://doi.org/10.4155/fmc-2016-0189.CrossRef

35.

Bae DG, Kim TD, Li G, Yoon WH, Chae CB. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin Cancer Res. 2005;11(7):2651–61.CrossRefPubMed

36.

Huang S, New L, Pan Z, Han J, Nemerow GR. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem. 2000;275(16):12266–72.CrossRefPubMed

37.

Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther. 2004;10(6):1032–42.CrossRefPubMed

38.

Stradal T, Courtney KD, Rottner K, Hahne P, Small JV, Pendergast AM. The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia. Curr Biol. 2001;11(11):891–5.CrossRefPubMed

39.

Leng Y, Zhang J, Badour K, Arpaia E, Freeman S, Cheung P, et al. Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation. Proc Natl Acad Sci U S A. 2005;102(4):1098–103.CrossRefPubMedPubMedCentral

40.

Innocenti M, Zucconi A, Disanza A, Frittoli E, Areces LB, Steffen A, et al. Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nat Cell Biol. 2004;6(4):319–27.CrossRefPubMed

41.

Tani K, Sato S, Sukezane T, Kojima H, Hirose H, Hanafusa H, et al. Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian enabled (Mena) by c-Abl kinase. J Biol Chem. 2003 Jun 13; 278(24):21685-92. Mol Cell Biol. 2004;24(11):4979–93.CrossRef

42.

Echarri A, Lai MJ, Robinson MR, Pendergast AM. Abl interactor 1 (Abi-1) wave-binding and SNARE domains regulate its nucleocytoplasmic shuttling, lamellipodium localization, and wave-1 levels. Mol Cell Biol. 2004;24(11):4979–93.CrossRefPubMedPubMedCentral

43.

Nimnual A, Bar-Sagi D. The two hats of SOS. Sci STKE. 2002;2002(145):pe36.PubMed

44.

Sekino S, Kashiwagi Y, Kanazawa H, Takada K, Baba T, Sato S, et al. The NESH/Abi-3-based WAVE2 complex is functionally distinct from the Abi-1-based WAVE2 complex. Cell Commun Signal. 2015;13:41. https://doi.org/10.1186/s12964-015-0119-5.CrossRefPubMedPubMedCentral

45.

Joliot A, Prochiantz A. Transduction peptides: from technology to physiology [J]. Nat Cell Biol. 2004;6(3):189–96.CrossRefPubMed

46.

Willier S, Butt E, Grunewald TG. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell. 2013;105(8):317–33. https://doi.org/10.1111/boc.201300011.CrossRefPubMed

47.

Shi Y, Alin K, Goff SP. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev. 1995 Nov 1;9(21):2583–97.CrossRefPubMed

Title: Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells
Authors: Xuechen Yu
Chuan Liang
Yuanzhen Zhang
Wei Zhang
Huijun Chen
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Metastasis
Ovarian Cancer
Ovarian Cancer
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-6087-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Evaluation of gene-environment interactions for colorectal cancer susceptibility loci using case-only and case-control designs

The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer

Occupational exposure to formaldehyde and risk of non hodgkin lymphoma: a meta-analysis

The effects of photodynamic therapy on leukemia cells mediated by KillerRed, a genetically encoded fluorescent protein photosensitizer

Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma

Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer